For the first time, we found that miR-15b-5p/miR-92b-3p mimics could inhibit MAOA activity through directly targeting PTGS1 via NF-κB1/SP1 signaling and may be developed as new drug targets for depression treatment in OSA patients. Here, SP1 is linked to major depressive disorder.